Articles related to BLEEDING/BLOOD DISORDERS

Hemoglobin disorders represent the single largest category of genetic disorders in the United States after chromosomal disorders, yet there is no systematic approach to managing them despite excellent guidelines from NHLBI, ASH, and NASCC.

Rates of major bleeding for therapeutic-dose apixaban and dabigatran were similar to those for low-dose aspirin, whereas rates were higher for rivaroxaban.

Cancer correlation analysis reveals that persistent thrombocytosis at six months carries an 18.1% cancer risk in males and 10.1% in females, with lung and colorectal malignancies predominating.

Careful attention to laboratory markers combined with thorough clinical assessment allows for precise classification of anemia type, enabling targeted treatment approaches.

In this randomized trial of 1,010 patients with stable DES undergoing noncardiac surgery, perioperative aspirin continuation showed no significant reduction in major adverse cardiac events compared to complete antiplatelet cessation.

In a comprehensive Bayesian network meta-analysis, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a significant reduction in major bleeding compared to the conventional 12 months of DAPT, without an increase in MACCE.